Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 964-972

  Dubey, Raghvendra K ^a,b   Jackson, Edwin K ^a   Gillespie, Delbert G ^a   Zacharia, Lefteris C ^a   Imthurn, Bruno ^b   Keller, Paul J ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular disease mitogen activated protein kinase; Estrogens; Postmenopausal women; Vascular smooth muscle

Indexed keywords

ESTRADIOL; ESTRADIOL CIPIONATE; ESTRIOL; ESTROGEN; ESTRONE SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN ACTIVITY; GROWTH INHIBITION; HEART PROTECTION; HUMAN; HUMAN TISSUE; MUSCLE GROWTH; PRIORITY JOURNAL; RECEPTOR BINDING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0034127782     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.964     Document Type: Article

References (38)

1. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330-352.
2. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med. 1985;313:1038-1043.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
5. Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol. 1976;19:775-788.
6. Stumpf P. Estrogen replacement therapy: current regimens. In: Swartz DP, eds. Hormone Replacement Therapy. Baltimore, Md: Williams and Wilkins; 1992:171-190.
7. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donell TF Jr, Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med. 1997;3:545-548.
8. Losordo DW, Kearney M, Kim EA, Jekanowski, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1994;1501-1510.
9. Wakeling AE, Bowler J. ICI 182,780, a new antiestrogen with clinical potential. J Steroid Biochem Mol Biol. 1992;43:173-177.
10. Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguere V. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and β. Endocrinology. 1998;139: 111-118.
11. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension. 1998;33(pt 2):177-182.
12. Oparil S, Levine RL, Chen YF. Sex hormones and the vasculature. In: Sowers JR, Walsh M, eds. Endocrinology of the Vasculature. Totawa, NJ: Humana Press Inc; 1996:225-237.
13. Rosselli M, Keller PJ, Kern F, Hahn AWA, Dubey RK. Estradiol inhibits mitogen-induced proliferation and migration of human aortic smooth muscle cells: implications for cardiovascular disease in women. Circulation. 1994;90(suppl I):I-87. Abstract.
14. Oparil S, Levine R, Chen S-J, Durand J, Chen YF. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1997;95:1301-1307.
15. Foegh M, Asotra S, Howell M, Ramwell P. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg. 1994;14: 722-726.
16. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A2b receptors. Hypertension. 1998;31(pt 2):516-521.
17. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptors. Circulation. 1994;89: 1943-1950.
18. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin like growth factor-I and platelet-derived growth factor-BB induce directed migration of human aortic smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
19. Colburn P, Buonassisi V. Estrogen binding sites in endothelial cell cultures. Science. 1978;201:817-819.
20. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, Levin ER. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J. 1998;330:1097-1105.
21. Kim-Schulze S, Lowe WL Jr, Schnaper HW. Estrogen-stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor. Circulation. 1998;98:413-421.
22. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation. 1999;99:2688-2693.
23. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17β-Estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension. 1998;31(pt 2):522-528.
24. Schoultz B von. Potency of different estrogens. In: Studd JWW, Greenblatt RB, eds. The Menopause. Oxford/London, UK: Blackwell Scientific Publications; 1992:171-190.
25. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation. 1997;95:1505-1514.
26. Akishita M, Kozaki K, Eto M, Yoshizumi M, Ishikawa M, Toba K, Orimo H, Ouchi Y. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun. 1998;251:17-21.
27. Dubey RK, Tyurina YY, Tyurin VA, Gillespie D, Branch RA, Jackson EK, Kagan VE. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res. 1999;84:229-239.
28. MacDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ. 1991;303:435-437.
29. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94:2221-2227.
30. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone replacement therapy on endogenous nitric oxide (nitrate/nitrite) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab. 1997;82:388-394.
31. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two year follow-up study. Hypertension. 1995;25:848-853.
32. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension. 1998;31(pt 2):152-161.
33. Pyles JM, March KL, Franklin M, Mehdi K, Wilensky RL, Adam LP. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries. Circ Res. 1997;81:904-910.
34. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation. 1997;95:1768-1772.
35. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 1996;98:36-42.
36. Baron YM, Galea R, Brincat M. Carotid artery wall changes in estrogen-treated and -untreated postmenopausal women. Obstet Gynecol. 1998;91: 982-986.
37. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev. 1990;70:1177-1198.
38. Anderson JR, ed. Muir's Textbook of Pathology. London, UK: E Arnold; 1982:360-394.